トランスクリプトミクス技術の世界市場

トランスクリプトミクス技術の世界市場は2030年までに120億米ドルに達する見込み

2024年に79億米ドルと推定されるトランスクリプトミクス技術の世界市場は、2024年から2030年にかけてCAGR 7.2%で成長し、2030年には120億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるトランスクリプトミクス消耗品は、CAGR 5.3%を記録し、分析期間終了までに47億米ドルに達すると予測されます。トランスクリプトミクス機器セグメントの成長率は、分析期間でCAGR 9.2%と推定されます。

米国市場は21億米ドルと推定、中国はCAGR7.1％で成長予測

米国のトランスクリプトミクス技術市場は、2024年に21億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに19億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは7.1%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ6.4％と6.3％と予測されています。欧州では、ドイツがCAGR約6.0％で成長すると予測されています。

世界の「トランスクリプトミクス技術」市場- 主要動向と促進要因のまとめ

なぜトランスクリプトミクスがプレシジョン・メディシンの時代の中心的役割を担っているのか？

トランスクリプトミクス（ゲノムから産生されるRNA転写物の包括的な調査）は、現代の生物医学研究、特に精密医療の拡大する領域における基礎へと急速に発展しています。異なる組織、細胞タイプ、病態における遺伝子の動的発現を分析することにより、トランスクリプトミクスは細胞機能と病理学に対する比類ない洞察を提供します。この能力は、科学者が病気を診断し、バイオマーカーを同定し、標的治療のために患者を層別化する方法を一変させました。COVID-19のパンデミックは、研究者がRNAプロファイリングを用いてウイルスの進化と宿主の反応を追跡したため、トランスクリプトミクスを含むオミックス技術に対する世界の認知を著しく加速させました。腫瘍学では、トランスクリプトーム解析は腫瘍の不均一性を理解し、新規創薬標的を同定するために頻繁に使用されるようになりました。さらに、希少疾患の調査では、トランスクリプトーム解析による画期的な進歩が見られ、単発性疾患の分類と理解を深めることができるようになりました。バイオファーマ企業が個別化治療薬への投資を深めるにつれ、創薬、トキシコゲノミクス、臨床試験の最適化におけるトランスクリプトミクスの役割は劇的に拡大しています。このように臨床的、商業的な関連性が高まっていることは、トランスクリプトミクスが単なる研究ツールではなく、次世代の診断薬や治療薬の基礎となるものと見なされるようになった理由を明確に示しています。

次世代シーケンサーとバイオインフォマティクスはトランスクリプトミクスのイノベーションをどのように後押ししているのか？

トランスクリプトミクスの爆発的な成長は、次世代シーケンス（NGS）、シングルセルRNAシーケンス（scRNA-seq）、高スループットマイクロアレイプラットフォームにおける技術的ブレークスルーのおかげです。これらのツールにより、研究者はこれまでにない分解能とスケールで遺伝子発現データを取得し、遺伝子活性の大まかな動向と微妙な変化の両方を明らかにすることができます。特にシングルセル技術は、トランスクリプトームを個々の細胞レベルでマッピングすることにより、この分野に革命をもたらし、これまで隠されていた細胞サブタイプや疾患メカニズムを明らかにしています。一方、ロングリードシーケンス技術の進歩は、転写産物のアイソフォーム検出や代替スプライシング解析における限界に対処しつつあります。しかし、トランスクリプトミクス研究から生成される膨大なデータは、結果を管理、解釈、可視化するための高度な計算ツールを必要とします。複雑なパターンを同定し、遺伝子機能を予測し、細胞タイプを自動分類するために、AIや機械学習モデルがますます適用されるようになっています。クラウドベースのバイオインフォマティクス・プラットフォームとオープンソースのデータベースにより、これらの強力なツールは世界中の研究者が利用しやすくなっています。このようなウェットラボのイノベーションとドライラボのアナリティクスの統合は、トランスクリプトミクスの有用性を拡大するだけでなく、複数の治療領域にわたって、発見までの時間を加速しています。

トランスクリプトミクス技術はゲノミクスと機能生物学のギャップを埋められるか？

ゲノミクスが生命の設計図を明らかにするのに対し、トランスクリプトミクスは、その設計図が様々な生物学的・環境的条件下でどのように解釈されるかをリアルタイムでスナップショットとして提供します。この違いにより、トランスクリプトミクスは、遺伝子活性を文脈の中で理解することが重要な機能ゲノミクスやシステム生物学にとって不可欠なものとなっています。例えば免疫学では、トランスクリプトミクス・プロファイリングは免疫細胞の活性化をモニターし、自己免疫疾患やワクチン反応に関連するサイトカインシグネチャーを同定するために用いられています。神経科学の調査では、脳細胞の多様性や神経変性疾患経路を探るために、空間トランスクリプトミクス（組織構造内の遺伝子発現をマッピングする新しい手法）への依存度が高まっています。環境トランスクリプトミクスは、気候変動や汚染に対する動植物のストレス応答を生態学者が評価するのに役立っています。農業ゲノミクスもトランスクリプトミクスの恩恵を受けており、収量やストレス耐性、害虫に対する抵抗性を向上させた作物の育種を可能にしています。このような分野横断的な応用は、トランスクリプトミクスが静的なゲノムデータと動的な細胞機能との間の重要なギャップを埋めるものであり、ヘルスケアのみならず、より広範なライフサイエンス・エコシステムにおいて不可欠なものであるというコンセンサスの高まりを反映しています。

トランスクリプトミクス技術市場の成長はいくつかの要因に牽引されている...

トランスクリプトミクス技術市場の成長は、研究需要、技術の成熟度、エンドユーザーの拡大に関連するいくつかの要因によって牽引されています。主要な触媒は個別化医療の台頭であり、RNAプロファイリングは患者固有の疾患経路を特定し、治療を調整する上で中心的な役割を果たしています。政府と民間投資家の双方によるライフサイエンス研究への資金提供の増加は、腫瘍学、感染症、神経生物学などの分野における大規模トランスクリプトミクス研究を支えています。シングルセルシーケンス、空間トランスクリプトミクス、ハイスループットオートメーションなどの技術的進歩により、より広範で詳細なトランスクリプトミクス解析が低コストで可能となっています。製薬会社はトランスクリプトミクスを医薬品開発パイプラインに組み入れ、化合物のリスク除去、オフターゲット効果の解明、規制当局による承認プロセスの迅速化を図っています。臨床検査室はトランスクリプトーム・パネルを診断ツールとして採用し始めており、特に腫瘍学と希少疾患検査において顕著です。さらに、バイオインフォマティクス・プラットフォームとユーザーフレンドリーなデータ可視化ツールの普及は、トランスクリプトミクスを民主化し、学術界と産業界の研究者に同様に力を与えています。規制の枠組みもトランスクリプトミクスに基づく診断薬に対応するよう徐々に適応しつつあり、商業化への新たな道が開かれつつあります。これらの要因が相まって、トランスクリプトミクスはニッチな科学的手法から生物医学と生命科学の革新に不可欠なエンジンへと変貌しつつあります。

セグメント

タイプ（消耗品、機器、ソフトウェア、サービス）、テクノロジー（マイクロアレイ、qPCR、シーケンステクノロジー）、アプリケーション（創薬、診断・疾患プロファイリング、その他アプリケーション）

調査対象企業の例（全32社）

• 10x Genomics
• Agilent Technologies Inc.
• Becton, Dickinson and Company（BD）
• Bio-Rad Laboratories, Inc.
• BGI Genomics
• Danaher Corporation
• Fluidigm Corporation
• F. Hoffmann-La Roche Ltd
• GE Healthcare
• Illumina, Inc.
• LC Sciences, LLC
• Merck KGaA
• NanoString Technologies, Inc.
• PerkinElmer Inc.
• Promega Corporation
• Qiagen N.V.
• Revvity, Inc.
• Takara Bio Inc.
• Thermo Fisher Scientific Inc.
• Vizgen, Inc.

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・産業団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストの厳選されたグループを含む1万4,949人のエコノミストを追跡しています。我々の16,491以上のレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• その他欧州
• アジア太平洋
• その他の地域

第4章 競合

Global Transcriptomics Technologies Market to Reach US$12.0 Billion by 2030

The global market for Transcriptomics Technologies estimated at US$7.9 Billion in the year 2024, is expected to reach US$12.0 Billion by 2030, growing at a CAGR of 7.2% over the analysis period 2024-2030. Transcriptomics Consumables, one of the segments analyzed in the report, is expected to record a 5.3% CAGR and reach US$4.7 Billion by the end of the analysis period. Growth in the Transcriptomics Instruments segment is estimated at 9.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.1 Billion While China is Forecast to Grow at 7.1% CAGR

The Transcriptomics Technologies market in the U.S. is estimated at US$2.1 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.9 Billion by the year 2030 trailing a CAGR of 7.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.4% and 6.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.0% CAGR.

Global "Transcriptomics Technologies" Market - Key Trends & Drivers Summarized

Why Is Transcriptomics Taking Center Stage in the Era of Precision Medicine?

Transcriptomics-the comprehensive study of RNA transcripts produced by the genome-has rapidly evolved into a cornerstone of modern biomedical research, especially within the expanding domain of precision medicine. By analyzing the dynamic expression of genes in different tissues, cell types, and disease states, transcriptomics offers unparalleled insights into cellular function and pathology. This capability has transformed how scientists diagnose diseases, identify biomarkers, and stratify patients for targeted therapies. The COVID-19 pandemic notably accelerated global awareness of omics technologies, including transcriptomics, as researchers used RNA profiling to track viral evolution and host responses. In oncology, transcriptome sequencing is now frequently used to understand tumor heterogeneity and identify novel drug targets. Additionally, rare disease research has seen breakthroughs through transcriptomic analysis, allowing for better classification and understanding of monogenic disorders. As biopharma companies deepen their investment in personalized therapeutics, the role of transcriptomics in drug discovery, toxicogenomics, and clinical trial optimization has expanded dramatically. This growing clinical and commercial relevance underscores why transcriptomics technologies are now regarded not just as research tools but as foundational to the next generation of diagnostics and therapeutics.

How Are Next-Gen Sequencing and Bioinformatics Powering Transcriptomics Innovation?

The explosive growth of transcriptomics owes much to technological breakthroughs in next-generation sequencing (NGS), single-cell RNA sequencing (scRNA-seq), and high-throughput microarray platforms. These tools enable researchers to capture gene expression data at unprecedented resolution and scale, revealing both broad trends and subtle variations in gene activity. Single-cell techniques, in particular, are revolutionizing the field by mapping transcriptomes at the level of individual cells, uncovering previously hidden cell subtypes and disease mechanisms. Meanwhile, advancements in long-read sequencing technologies are addressing limitations in transcript isoform detection and alternative splicing analysis. However, the deluge of data generated from transcriptomics studies requires sophisticated computational tools to manage, interpret, and visualize results. AI and machine learning models are increasingly applied to identify complex patterns, predict gene function, and automate the classification of cell types. Cloud-based bioinformatics platforms and open-source databases have made these powerful tools more accessible to researchers around the world. This integration of wet-lab innovation with dry-lab analytics is not only expanding the utility of transcriptomics but also accelerating the time-to-discovery across multiple therapeutic areas.

Can Transcriptomics Technologies Bridge the Gap Between Genomics and Functional Biology?

While genomics reveals the blueprint of life, transcriptomics provides real-time snapshots of how that blueprint is interpreted under varying biological and environmental conditions. This distinction has made transcriptomics essential for functional genomics and systems biology, where understanding gene activity in context is critical. In immunology, for example, transcriptomic profiling is being used to monitor immune cell activation and identify cytokine signatures associated with autoimmune diseases or vaccine responses. Neuroscience research is increasingly reliant on spatial transcriptomics-an emerging method that maps gene expression within tissue architecture-to explore brain cell diversity and neurodegenerative disease pathways. Environmental transcriptomics is another fast-emerging application, helping ecologists assess stress responses in plants and animals to climate change and pollution. Agricultural genomics also benefits from transcriptomics, enabling the breeding of crops with improved yield, stress tolerance, and resistance to pests. These cross-sector applications reflect a growing consensus that transcriptomics bridges the critical gap between static genomic data and dynamic cellular function, making it indispensable not just in healthcare, but across the broader life sciences ecosystem.

The Growth in the Transcriptomics Technologies Market Is Driven by Several Factors…

The growth in the transcriptomics technologies market is driven by several factors linked to research demand, technological maturity, and end-user expansion. A key catalyst is the rise of personalized medicine, where RNA profiling plays a central role in identifying patient-specific disease pathways and tailoring treatments. Increased funding for life sciences research-by both governments and private investors-is supporting large-scale transcriptomics studies in areas like oncology, infectious disease, and neurobiology. Technological advancements such as single-cell sequencing, spatial transcriptomics, and high-throughput automation are enabling broader, more detailed transcriptomic analyses at lower costs. Pharmaceutical companies are incorporating transcriptomics into drug development pipelines to de-risk compounds, understand off-target effects, and accelerate regulatory approval processes. Clinical laboratories are beginning to adopt transcriptomic panels as diagnostic tools, particularly in oncology and rare disease testing. Furthermore, the proliferation of bioinformatics platforms and user-friendly data visualization tools has democratized transcriptomics, empowering researchers in academia and industry alike. Regulatory frameworks are gradually adapting to accommodate transcriptomics-based diagnostics, opening new pathways for commercialization. Collectively, these drivers are transforming transcriptomics from a niche scientific method into a vital engine of biomedical and life science innovation.

SCOPE OF STUDY:

The report analyzes the Transcriptomics Technologies market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Consumables, Instruments, Software, Services); Technology (Microarrays, qPCR, Sequencing Technology); Application (Drug Discovery, Diagnostics & Disease Profiling, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 32 Featured) -

• 10x Genomics
• Agilent Technologies Inc.
• Becton, Dickinson and Company (BD)
• Bio-Rad Laboratories, Inc.
• BGI Genomics
• Danaher Corporation
• Fluidigm Corporation
• F. Hoffmann-La Roche Ltd
• GE Healthcare
• Illumina, Inc.
• LC Sciences, LLC
• Merck KGaA
• NanoString Technologies, Inc.
• PerkinElmer Inc.
• Promega Corporation
• Qiagen N.V.
• Revvity, Inc.
• Takara Bio Inc.
• Thermo Fisher Scientific Inc.
• Vizgen, Inc.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Transcriptomics Technologies - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Surge in Precision Medicine and Personalized Therapy Drives Transcriptomics Adoption
  • Rapid Advances in RNA Sequencing Technologies Throw the Spotlight on Omics Integration
  • Expanding Applications in Oncology and Rare Disease Research Propel Market Growth
  • Increasing Role of Transcriptomics in Drug Discovery and Target Validation Spurs Demand
  • Expansion of Single-Cell Analysis Capabilities Accelerates Innovation and Research Outcomes
  • Collaborations Between Biotech Companies and Research Institutions Expand Commercialization Scope
  • Growing Utility of Non-Coding RNA Analysis Opens Up New Revenue Streams
  • Development of Multi-Omics Platforms Sustains Demand for High-Throughput Transcriptomics
  • Accelerating Trend Toward Predictive Diagnostics Expands the Addressable Market
  • Rising Use of Transcriptomics in Agriculture and Environmental Science Broadens Market Applications
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Transcriptomics Technologies Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Transcriptomics Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World 6-Year Perspective for Transcriptomics Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
  • TABLE 4: World Recent Past, Current & Future Analysis for Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 5: World 6-Year Perspective for Consumables by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 6: World Recent Past, Current & Future Analysis for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 7: World 6-Year Perspective for Instruments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Software by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World 6-Year Perspective for Software by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 10: World Recent Past, Current & Future Analysis for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 11: World 6-Year Perspective for Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 12: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 13: World 6-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Drug Discovery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World 6-Year Perspective for Drug Discovery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 16: World Recent Past, Current & Future Analysis for Diagnostics & Disease Profiling by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 17: World 6-Year Perspective for Diagnostics & Disease Profiling by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 18: World Recent Past, Current & Future Analysis for Microarrays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 19: World 6-Year Perspective for Microarrays by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for qPCR by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World 6-Year Perspective for qPCR by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 22: World Recent Past, Current & Future Analysis for Sequencing Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 23: World 6-Year Perspective for Sequencing Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Transcriptomics Technologies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 24: USA Recent Past, Current & Future Analysis for Transcriptomics Technologies by Type - Consumables, Instruments, Software and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 25: USA 6-Year Perspective for Transcriptomics Technologies by Type - Percentage Breakdown of Value Sales for Consumables, Instruments, Software and Services for the Years 2025 & 2030
  • TABLE 26: USA Recent Past, Current & Future Analysis for Transcriptomics Technologies by Application - Other Applications, Drug Discovery and Diagnostics & Disease Profiling - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 27: USA 6-Year Perspective for Transcriptomics Technologies by Application - Percentage Breakdown of Value Sales for Other Applications, Drug Discovery and Diagnostics & Disease Profiling for the Years 2025 & 2030
  • TABLE 28: USA Recent Past, Current & Future Analysis for Transcriptomics Technologies by Technology - Microarrays, qPCR and Sequencing Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 29: USA 6-Year Perspective for Transcriptomics Technologies by Technology - Percentage Breakdown of Value Sales for Microarrays, qPCR and Sequencing Technology for the Years 2025 & 2030
• CANADA
  • TABLE 30: Canada Recent Past, Current & Future Analysis for Transcriptomics Technologies by Type - Consumables, Instruments, Software and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 31: Canada 6-Year Perspective for Transcriptomics Technologies by Type - Percentage Breakdown of Value Sales for Consumables, Instruments, Software and Services for the Years 2025 & 2030
  • TABLE 32: Canada Recent Past, Current & Future Analysis for Transcriptomics Technologies by Application - Other Applications, Drug Discovery and Diagnostics & Disease Profiling - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 33: Canada 6-Year Perspective for Transcriptomics Technologies by Application - Percentage Breakdown of Value Sales for Other Applications, Drug Discovery and Diagnostics & Disease Profiling for the Years 2025 & 2030
  • TABLE 34: Canada Recent Past, Current & Future Analysis for Transcriptomics Technologies by Technology - Microarrays, qPCR and Sequencing Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 35: Canada 6-Year Perspective for Transcriptomics Technologies by Technology - Percentage Breakdown of Value Sales for Microarrays, qPCR and Sequencing Technology for the Years 2025 & 2030
• JAPAN
  • Transcriptomics Technologies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 36: Japan Recent Past, Current & Future Analysis for Transcriptomics Technologies by Type - Consumables, Instruments, Software and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 37: Japan 6-Year Perspective for Transcriptomics Technologies by Type - Percentage Breakdown of Value Sales for Consumables, Instruments, Software and Services for the Years 2025 & 2030
  • TABLE 38: Japan Recent Past, Current & Future Analysis for Transcriptomics Technologies by Application - Other Applications, Drug Discovery and Diagnostics & Disease Profiling - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 39: Japan 6-Year Perspective for Transcriptomics Technologies by Application - Percentage Breakdown of Value Sales for Other Applications, Drug Discovery and Diagnostics & Disease Profiling for the Years 2025 & 2030
  • TABLE 40: Japan Recent Past, Current & Future Analysis for Transcriptomics Technologies by Technology - Microarrays, qPCR and Sequencing Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 41: Japan 6-Year Perspective for Transcriptomics Technologies by Technology - Percentage Breakdown of Value Sales for Microarrays, qPCR and Sequencing Technology for the Years 2025 & 2030
• CHINA
  • Transcriptomics Technologies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 42: China Recent Past, Current & Future Analysis for Transcriptomics Technologies by Type - Consumables, Instruments, Software and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 43: China 6-Year Perspective for Transcriptomics Technologies by Type - Percentage Breakdown of Value Sales for Consumables, Instruments, Software and Services for the Years 2025 & 2030
  • TABLE 44: China Recent Past, Current & Future Analysis for Transcriptomics Technologies by Application - Other Applications, Drug Discovery and Diagnostics & Disease Profiling - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: China 6-Year Perspective for Transcriptomics Technologies by Application - Percentage Breakdown of Value Sales for Other Applications, Drug Discovery and Diagnostics & Disease Profiling for the Years 2025 & 2030
  • TABLE 46: China Recent Past, Current & Future Analysis for Transcriptomics Technologies by Technology - Microarrays, qPCR and Sequencing Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 47: China 6-Year Perspective for Transcriptomics Technologies by Technology - Percentage Breakdown of Value Sales for Microarrays, qPCR and Sequencing Technology for the Years 2025 & 2030
• EUROPE
  • Transcriptomics Technologies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 48: Europe Recent Past, Current & Future Analysis for Transcriptomics Technologies by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 49: Europe 6-Year Perspective for Transcriptomics Technologies by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
  • TABLE 50: Europe Recent Past, Current & Future Analysis for Transcriptomics Technologies by Type - Consumables, Instruments, Software and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Europe 6-Year Perspective for Transcriptomics Technologies by Type - Percentage Breakdown of Value Sales for Consumables, Instruments, Software and Services for the Years 2025 & 2030
  • TABLE 52: Europe Recent Past, Current & Future Analysis for Transcriptomics Technologies by Application - Other Applications, Drug Discovery and Diagnostics & Disease Profiling - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 53: Europe 6-Year Perspective for Transcriptomics Technologies by Application - Percentage Breakdown of Value Sales for Other Applications, Drug Discovery and Diagnostics & Disease Profiling for the Years 2025 & 2030
  • TABLE 54: Europe Recent Past, Current & Future Analysis for Transcriptomics Technologies by Technology - Microarrays, qPCR and Sequencing Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 55: Europe 6-Year Perspective for Transcriptomics Technologies by Technology - Percentage Breakdown of Value Sales for Microarrays, qPCR and Sequencing Technology for the Years 2025 & 2030
• FRANCE
  • Transcriptomics Technologies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 56: France Recent Past, Current & Future Analysis for Transcriptomics Technologies by Type - Consumables, Instruments, Software and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: France 6-Year Perspective for Transcriptomics Technologies by Type - Percentage Breakdown of Value Sales for Consumables, Instruments, Software and Services for the Years 2025 & 2030
  • TABLE 58: France Recent Past, Current & Future Analysis for Transcriptomics Technologies by Application - Other Applications, Drug Discovery and Diagnostics & Disease Profiling - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 59: France 6-Year Perspective for Transcriptomics Technologies by Application - Percentage Breakdown of Value Sales for Other Applications, Drug Discovery and Diagnostics & Disease Profiling for the Years 2025 & 2030
  • TABLE 60: France Recent Past, Current & Future Analysis for Transcriptomics Technologies by Technology - Microarrays, qPCR and Sequencing Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 61: France 6-Year Perspective for Transcriptomics Technologies by Technology - Percentage Breakdown of Value Sales for Microarrays, qPCR and Sequencing Technology for the Years 2025 & 2030
• GERMANY
  • Transcriptomics Technologies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 62: Germany Recent Past, Current & Future Analysis for Transcriptomics Technologies by Type - Consumables, Instruments, Software and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Germany 6-Year Perspective for Transcriptomics Technologies by Type - Percentage Breakdown of Value Sales for Consumables, Instruments, Software and Services for the Years 2025 & 2030
  • TABLE 64: Germany Recent Past, Current & Future Analysis for Transcriptomics Technologies by Application - Other Applications, Drug Discovery and Diagnostics & Disease Profiling - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 65: Germany 6-Year Perspective for Transcriptomics Technologies by Application - Percentage Breakdown of Value Sales for Other Applications, Drug Discovery and Diagnostics & Disease Profiling for the Years 2025 & 2030
  • TABLE 66: Germany Recent Past, Current & Future Analysis for Transcriptomics Technologies by Technology - Microarrays, qPCR and Sequencing Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 67: Germany 6-Year Perspective for Transcriptomics Technologies by Technology - Percentage Breakdown of Value Sales for Microarrays, qPCR and Sequencing Technology for the Years 2025 & 2030
• ITALY
  • TABLE 68: Italy Recent Past, Current & Future Analysis for Transcriptomics Technologies by Type - Consumables, Instruments, Software and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Italy 6-Year Perspective for Transcriptomics Technologies by Type - Percentage Breakdown of Value Sales for Consumables, Instruments, Software and Services for the Years 2025 & 2030
  • TABLE 70: Italy Recent Past, Current & Future Analysis for Transcriptomics Technologies by Application - Other Applications, Drug Discovery and Diagnostics & Disease Profiling - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 71: Italy 6-Year Perspective for Transcriptomics Technologies by Application - Percentage Breakdown of Value Sales for Other Applications, Drug Discovery and Diagnostics & Disease Profiling for the Years 2025 & 2030
  • TABLE 72: Italy Recent Past, Current & Future Analysis for Transcriptomics Technologies by Technology - Microarrays, qPCR and Sequencing Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 73: Italy 6-Year Perspective for Transcriptomics Technologies by Technology - Percentage Breakdown of Value Sales for Microarrays, qPCR and Sequencing Technology for the Years 2025 & 2030
• UNITED KINGDOM
  • Transcriptomics Technologies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 74: UK Recent Past, Current & Future Analysis for Transcriptomics Technologies by Type - Consumables, Instruments, Software and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: UK 6-Year Perspective for Transcriptomics Technologies by Type - Percentage Breakdown of Value Sales for Consumables, Instruments, Software and Services for the Years 2025 & 2030
  • TABLE 76: UK Recent Past, Current & Future Analysis for Transcriptomics Technologies by Application - Other Applications, Drug Discovery and Diagnostics & Disease Profiling - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 77: UK 6-Year Perspective for Transcriptomics Technologies by Application - Percentage Breakdown of Value Sales for Other Applications, Drug Discovery and Diagnostics & Disease Profiling for the Years 2025 & 2030
  • TABLE 78: UK Recent Past, Current & Future Analysis for Transcriptomics Technologies by Technology - Microarrays, qPCR and Sequencing Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 79: UK 6-Year Perspective for Transcriptomics Technologies by Technology - Percentage Breakdown of Value Sales for Microarrays, qPCR and Sequencing Technology for the Years 2025 & 2030
• REST OF EUROPE
  • TABLE 80: Rest of Europe Recent Past, Current & Future Analysis for Transcriptomics Technologies by Type - Consumables, Instruments, Software and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Rest of Europe 6-Year Perspective for Transcriptomics Technologies by Type - Percentage Breakdown of Value Sales for Consumables, Instruments, Software and Services for the Years 2025 & 2030
  • TABLE 82: Rest of Europe Recent Past, Current & Future Analysis for Transcriptomics Technologies by Application - Other Applications, Drug Discovery and Diagnostics & Disease Profiling - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 83: Rest of Europe 6-Year Perspective for Transcriptomics Technologies by Application - Percentage Breakdown of Value Sales for Other Applications, Drug Discovery and Diagnostics & Disease Profiling for the Years 2025 & 2030
  • TABLE 84: Rest of Europe Recent Past, Current & Future Analysis for Transcriptomics Technologies by Technology - Microarrays, qPCR and Sequencing Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 85: Rest of Europe 6-Year Perspective for Transcriptomics Technologies by Technology - Percentage Breakdown of Value Sales for Microarrays, qPCR and Sequencing Technology for the Years 2025 & 2030
• ASIA-PACIFIC
  • Transcriptomics Technologies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 86: Asia-Pacific Recent Past, Current & Future Analysis for Transcriptomics Technologies by Type - Consumables, Instruments, Software and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Asia-Pacific 6-Year Perspective for Transcriptomics Technologies by Type - Percentage Breakdown of Value Sales for Consumables, Instruments, Software and Services for the Years 2025 & 2030
  • TABLE 88: Asia-Pacific Recent Past, Current & Future Analysis for Transcriptomics Technologies by Application - Other Applications, Drug Discovery and Diagnostics & Disease Profiling - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 89: Asia-Pacific 6-Year Perspective for Transcriptomics Technologies by Application - Percentage Breakdown of Value Sales for Other Applications, Drug Discovery and Diagnostics & Disease Profiling for the Years 2025 & 2030
  • TABLE 90: Asia-Pacific Recent Past, Current & Future Analysis for Transcriptomics Technologies by Technology - Microarrays, qPCR and Sequencing Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 91: Asia-Pacific 6-Year Perspective for Transcriptomics Technologies by Technology - Percentage Breakdown of Value Sales for Microarrays, qPCR and Sequencing Technology for the Years 2025 & 2030
• REST OF WORLD
  • TABLE 92: Rest of World Recent Past, Current & Future Analysis for Transcriptomics Technologies by Type - Consumables, Instruments, Software and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Rest of World 6-Year Perspective for Transcriptomics Technologies by Type - Percentage Breakdown of Value Sales for Consumables, Instruments, Software and Services for the Years 2025 & 2030
  • TABLE 94: Rest of World Recent Past, Current & Future Analysis for Transcriptomics Technologies by Application - Other Applications, Drug Discovery and Diagnostics & Disease Profiling - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 95: Rest of World 6-Year Perspective for Transcriptomics Technologies by Application - Percentage Breakdown of Value Sales for Other Applications, Drug Discovery and Diagnostics & Disease Profiling for the Years 2025 & 2030
  • TABLE 96: Rest of World Recent Past, Current & Future Analysis for Transcriptomics Technologies by Technology - Microarrays, qPCR and Sequencing Technology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 97: Rest of World 6-Year Perspective for Transcriptomics Technologies by Technology - Percentage Breakdown of Value Sales for Microarrays, qPCR and Sequencing Technology for the Years 2025 & 2030

IV. COMPETITION